Aurothioglucose: Difference between revisions

Jump to navigation Jump to search
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{drugbox |
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447574504
| IUPAC_name = gold(I) (2''S'',3''S'',4''R'',5''S'')-3,4,5-trihydroxy-<br>6-(hydroxymethyl)-oxane-2-thiolate
| IUPAC_name = gold(I) (2''S'',3''S'',4''R'',5''S'')-3,4,5-trihydroxy-<br>6-(hydroxymethyl)-oxane-2-thiolate
| image = Authioglucose.png
| image = Authioglucose.png
Line 5: Line 7:
| image2 = Aurothioglucose-3D-vdW.png
| image2 = Aurothioglucose-3D-vdW.png
| width2 = 250
| width2 = 250
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|CDI|aurothioglucose}}
| MedlinePlus =
| licence_EU = <!-- EMEA requires brand name -->
| licence_US = <!-- FDA may use generic name -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- Not form found in UK - rather Sodium Aurothiomalate & Auranofin -->
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| dependency_liability = 
| routes_of_administration = [[Intramuscular injection]]
<!--Pharmacokinetic data-->
| bioavailability = 0%
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 12192-57-3
| CAS_number = 12192-57-3
| CAS_supplemental =
| ATC_prefix = M01
| ATC_prefix=M01
| ATC_suffix = CB04
| ATC_suffix=CB04
| ATC_supplemental =
| ATC_supplemental=  
| PubChem = 6104
| PubChem = 6104
| DrugBank =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| C=6 | H=11 | Au=1 | O=5 | S=1
| DrugBank =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1697725
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 16738764
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2P2V9Q0E78
 
<!--Chemical data-->
| C=6 | H=11 | Au=1 | O=5 | S=1  
| molecular_weight = 392.181 g/mol
| molecular_weight = 392.181 g/mol
| smiles = O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1S[Au]
| InChI = 1/C6H12O5S.Au/c7-1-2-3(8)4(9)5(10)6(12)11-2;/h2-10,12H,1H2;/q;+1/p-1/t2-,3-,4+,5-,6-;/m1./s1/rC6H11AuO5S/c7-13-6-5(11)4(10)3(9)2(1-8)12-6/h2-6,8-11H,1H2/t2-,3-,4+,5-,6-/m1/s1
| InChIKey = XHVAWZZCDCWGBK-MOEPNNSPBJ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H12O5S.Au/c7-1-2-3(8)4(9)5(10)6(12)11-2;/h2-10,12H,1H2;/q;+1/p-1/t2-,3-,4+,5-,6-;/m1./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XHVAWZZCDCWGBK-WYRLRVFGSA-M
| synonyms = Gold thioglucose, Solganal, Auromyose
| synonyms = Gold thioglucose, Solganal, Auromyose
| bioavailability = 0%
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| licence_EU =    <!-- EMEA requires brand name -->
| licence_US =    <!-- FDA may use generic name --> 
| pregnancy_AU =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US =  <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU =  <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA =  <!--                            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- Not form found in UK - rather Sodium Aurothiomalate & Auranofin -->
| legal_US =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =
| dependency_liability =
| routes_of_administration = [[intramuscular]] injection
}}
}}
              __NOTOC__
{{SI}}
{{SI}}
 
{{CMG}}


==Overview==
==Overview==
'''Aurothioglucose''', also known as gold thioglucose, is a [[chemical compound]] with the formula AuSC<sub>6</sub>H<sub>11</sub>O<sub>5</sub>. This derivative of the sugar [[glucose]] is used to treat [[rheumatoid arthritis]].
   
'''Aurothioglucose''', also known as gold thioglucose, is a [[chemical compound]] with the formula AuSC<sub>6</sub>H<sub>11</sub>O<sub>5</sub>. This derivative of the sugar [[glucose]] was formerly used to treat [[rheumatoid arthritis]].


==History==
==History==
{{main|Gold salts}}
{{main|Gold salts}}
Throughout history, gold was used to cure diseases, although the efficacy was not established. In 1935, gold drugs were reported to be effective for the treatment rheumatoid arthritis.<ref name=shaw>{{cite journal | author=Shaw, III, C. F. | title=Gold-Based Therapeutic Agents| journal=Chemical Reviews | year=1999 | volume=99 | pages=2589-600 | doi=10.1021/cr980431o}}</ref> Although many patients reacted positively to the drug, gold thioglucose was not uniformly effective.
Throughout history, gold was used to cure diseases, although the efficacy was not established. In 1935, gold drugs were reported to be effective for the treatment of [[rheumatoid arthritis]].<ref name=shaw>{{cite journal | author=Shaw, III, C. F. | title=Gold-Based Therapeutic Agents| journal=Chemical Reviews | year=1999 | volume=99 | pages=2589–600 | doi=10.1021/cr980431o | pmid=11749494 | issue=9}}</ref> Although many patients reacted positively to the drug, gold thioglucose was not uniformly effective.
 
Three gold drugs remain in active clinical use for this purpose in the United States: [[auranofin]], [[sodium aurothiomalate]] (gold sodium thiomalate) and aurothioglucose.  In the United Kingdom, only sodium aurothiomalate and auranofin are used.


Two gold drugs remain in active clinical use for this purpose in the United States: [[sodium aurothiomalate]] (gold sodium thiomalate) and Aurothioglucose, sold under the trade names Myochrysine and Solgonal, respectively.  In the United Kingdom, only sodium aurothiomalate and [[auranofin]] are used.
In 2001, aurothoglucose was withdrawn from the Dutch marked, where it had been the only injectable gold preparation available since 1943, forcing hospitals to change medication for a large number of patients to aurothiomalate.<ref>''Parenteral gold preparations. Efficacy and safety of therapy after switching from aurothioglucose to aurothiomalate'' (van Roon et al, J Rheumatol 2005)</ref> The drug had been in use for more than 70 years, and four years later the reasons for its sudden disappearance remained unclear.<ref>{{cite pmid|15940754}}</ref>


==Medicinal chemistry==
==Medicinal chemistry==
Line 49: Line 80:
Gold thioglucose features gold in the oxidation state of +I, like other gold thiolates. It is a water-soluble, non-ionic species that is assumed to exist as a polymer.<ref name=shaw/>  Under physiological conditions, an oxidation-reduction reaction leads to the formation of metallic gold and sulfinic acid derivative of thioglucose.
Gold thioglucose features gold in the oxidation state of +I, like other gold thiolates. It is a water-soluble, non-ionic species that is assumed to exist as a polymer.<ref name=shaw/>  Under physiological conditions, an oxidation-reduction reaction leads to the formation of metallic gold and sulfinic acid derivative of thioglucose.
:2 AuSTg  →  2 Au  +  TgSSTg
:2 AuSTg  →  2 Au  +  TgSSTg
:TgSSTg  +  H<sub>2</sub>O  →  TgSOH  +  TgSH  
:TgSSTg  +  H<sub>2</sub>O  →  TgSOH  +  TgSH
:2 TgSOH  →  TgSO<sub>2</sub>H  +  TgSH
:2 TgSOH  →  TgSO<sub>2</sub>H  +  TgSH
:Overall: 2 H<sub>2</sub>O  +  4 AuSTg  →  4 Au  +  TgSO<sub>2</sub>H  +  3 TgSH
:Overall: 2 H<sub>2</sub>O  +  4 AuSTg  →  4 Au  +  TgSO<sub>2</sub>H  +  3 TgSH
Line 58: Line 89:


==Miscellaneous observations==<!--lame, I know-->
==Miscellaneous observations==<!--lame, I know-->
In recent research, it has found that injection of gold thioglucose in the mouse induces obesity.<ref>{{cite journal | author = Naruta E, Buko V | title = Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose. | journal = Exp Toxicol Pathol | volume = 53 | issue = 5 | pages = 393-8 | year = 2001 | pmid=11817109}}</ref>  Aurothioglucose has an interaction with the [[antimalarial]] medication [[Hydroxychloroquine]].
In recent research, it was found that injection of gold thioglucose in the mouse induces obesity.<ref>{{cite journal | author = Naruta E, Buko V | title = Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose. | journal = Exp Toxicol Pathol | volume = 53 | issue = 5 | pages = 393–8 | year = 2001 | pmid=11817109 | doi = 10.1078/0940-2993-00205}}</ref>  Aurothioglucose has an interaction with the [[antimalarial]] medication [[hydroxychloroquine]].


==See also==
==See also==
Line 64: Line 95:


==References==
==References==
<references/>
                  {{Reflist|2}}   


==External links==
<!-- article needs more on its clinical use, cautions, side effects and monitoring. - Is this not covered by link to [[Gold salts]] ? -->
{{Anti-inflammatory and antirheumatic products}}




[[Category:Gold compounds]]
[[Category:Drug]]
[[Category:IARC Group 3 carcinogens]]
[[Category:IARC Group 3 carcinogens]]
[[Category:Coordination compounds]]
[[Category:Coordination compounds]]
[[Category:Immunosuppressive agents]]
[[Category:Organosulfur compounds]]
{{WH}}
{{WS}}

Latest revision as of 13:06, 13 April 2015

Aurothioglucose
Clinical data
SynonymsGold thioglucose, Solganal, Auromyose
AHFS/Drugs.comConsumer Drug Information
Routes of
administration
Intramuscular injection
ATC code
Pharmacokinetic data
Bioavailability0%
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6H11AuO5S
Molar mass392.181 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Aurothioglucose

Articles

Most recent articles on Aurothioglucose

Most cited articles on Aurothioglucose

Review articles on Aurothioglucose

Articles on Aurothioglucose in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Aurothioglucose

Images of Aurothioglucose

Photos of Aurothioglucose

Podcasts & MP3s on Aurothioglucose

Videos on Aurothioglucose

Evidence Based Medicine

Cochrane Collaboration on Aurothioglucose

Bandolier on Aurothioglucose

TRIP on Aurothioglucose

Clinical Trials

Ongoing Trials on Aurothioglucose at Clinical Trials.gov

Trial results on Aurothioglucose

Clinical Trials on Aurothioglucose at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Aurothioglucose

NICE Guidance on Aurothioglucose

NHS PRODIGY Guidance

FDA on Aurothioglucose

CDC on Aurothioglucose

Books

Books on Aurothioglucose

News

Aurothioglucose in the news

Be alerted to news on Aurothioglucose

News trends on Aurothioglucose

Commentary

Blogs on Aurothioglucose

Definitions

Definitions of Aurothioglucose

Patient Resources / Community

Patient resources on Aurothioglucose

Discussion groups on Aurothioglucose

Patient Handouts on Aurothioglucose

Directions to Hospitals Treating Aurothioglucose

Risk calculators and risk factors for Aurothioglucose

Healthcare Provider Resources

Symptoms of Aurothioglucose

Causes & Risk Factors for Aurothioglucose

Diagnostic studies for Aurothioglucose

Treatment of Aurothioglucose

Continuing Medical Education (CME)

CME Programs on Aurothioglucose

International

Aurothioglucose en Espanol

Aurothioglucose en Francais

Business

Aurothioglucose in the Marketplace

Patents on Aurothioglucose

Experimental / Informatics

List of terms related to Aurothioglucose

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Aurothioglucose, also known as gold thioglucose, is a chemical compound with the formula AuSC6H11O5. This derivative of the sugar glucose was formerly used to treat rheumatoid arthritis.

History

Throughout history, gold was used to cure diseases, although the efficacy was not established. In 1935, gold drugs were reported to be effective for the treatment of rheumatoid arthritis.[1] Although many patients reacted positively to the drug, gold thioglucose was not uniformly effective.

Three gold drugs remain in active clinical use for this purpose in the United States: auranofin, sodium aurothiomalate (gold sodium thiomalate) and aurothioglucose. In the United Kingdom, only sodium aurothiomalate and auranofin are used.

In 2001, aurothoglucose was withdrawn from the Dutch marked, where it had been the only injectable gold preparation available since 1943, forcing hospitals to change medication for a large number of patients to aurothiomalate.[2] The drug had been in use for more than 70 years, and four years later the reasons for its sudden disappearance remained unclear.[3]

Medicinal chemistry

Gold thioglucose features gold in the oxidation state of +I, like other gold thiolates. It is a water-soluble, non-ionic species that is assumed to exist as a polymer.[1] Under physiological conditions, an oxidation-reduction reaction leads to the formation of metallic gold and sulfinic acid derivative of thioglucose.

2 AuSTg → 2 Au + TgSSTg
TgSSTg + H2O → TgSOH + TgSH
2 TgSOH → TgSO2H + TgSH
Overall: 2 H2O + 4 AuSTg → 4 Au + TgSO2H + 3 TgSH

(where AuSTg = gold thioglucose, TgSSTg = thioglucose disulfide, TgSO2H = sulfinic acid derivative of thioglucose)

Preparation

Gold thioglucose can be prepared by treating gold bromide with thioglucose solution saturated with sulfur dioxide. Gold thioglucose is precipitated with methanol and recrystallized with water and methanol.

Miscellaneous observations

In recent research, it was found that injection of gold thioglucose in the mouse induces obesity.[4] Aurothioglucose has an interaction with the antimalarial medication hydroxychloroquine.

See also

References

  1. 1.0 1.1 Shaw, III, C. F. (1999). "Gold-Based Therapeutic Agents". Chemical Reviews. 99 (9): 2589–600. doi:10.1021/cr980431o. PMID 11749494.
  2. Parenteral gold preparations. Efficacy and safety of therapy after switching from aurothioglucose to aurothiomalate (van Roon et al, J Rheumatol 2005)
  3. PMID 15940754 (PMID 15940754)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  4. Naruta E, Buko V (2001). "Hypolipidemic effect of pantothenic acid derivatives in mice with hypothalamic obesity induced by aurothioglucose". Exp Toxicol Pathol. 53 (5): 393–8. doi:10.1078/0940-2993-00205. PMID 11817109.